Cannabinoids and Adverse Convulsive Effects: A Pharmacovigilance and Addictovigilance Analysis of Cases Reported in France
Fundamental & Clinical Pharmacology · 2025
DOI: 10.1111/fcp.70028 ↗Kurz gefasst
Fachartikel in der Zeitschrift Fundamental & Clinical Pharmacology, 2025. Verfasst von Marie-Laure Laroche und 4 weiteren Autor:innen. Beteiligte Einrichtung: Regional Centre of Pharmacovigilance, CHU Limoges, Limoges, France. Hauptthemen laut MEDLINE: Pharmacovigilance, Seizures, Cannabinoids. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Seizures after the use of cannabinoids are reported, but no precise descriptions of the characteristics of subjects and factors that may trigger seizures are available.
Objectives
To study the characteristics and circumstances associated with the occurrence of seizures in individuals using cannabinoids for medical or recreational purposes.
Methods
A retrospective analysis of spontaneous reports of adverse drug effects issued by the French pharmacovigilance and addictovigilance systems, and by manufacturers, extracted data from the Eudravigilance database (01/01/1985–21/07/2023). The request used the broad MedDRA SMQ term ‘convulsive’, with all products containing cannabinoids (THC, CBD, cannabis or natural cannabinoids).
Results
Among 4296 notifications with cannabinoids, 130 (3%) reports of convulsive effects were analysed: 29 cases (23.3%) related to medical use (27 CBD, 1 THC and 2 combined THC/CBD preparations) and 98 (75.4%) related to recreational use. The median age was 29.0 years (min‐max: 3–75), 78.7% were men and 81.1% were serious cases. Among the recreational users, 38.8% used Cannabis sativa with a history of epilepsy, and 68.4% of them were taking antiepileptics. In total, 67.7% of individuals had at least one risk factor for seizures, i.e., 31.0% among medical users and 78.6% among recreational users. The main risk factors with medical use were inefficacy of CBD (17.2%), fatigue (13.8%) and concomitant epileptogenic medications (10.3%). The main risk with recreational use was concomitant epileptogenic medications (39.8%), consumption of illicit drugs (33.7%) and alcohol (32.7%).
Conclusion
This analysis demonstrates the importance of alerting cannabinoid users, particularly recreational cannabis users and those with a history of epilepsy, about seizure‐associated risks. Moreover, educational information should be provided together with the prescription of licensed cannabinoids and medical cannabis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Regional Centre of Pharmacovigilance, CHU Limoges, Limoges, France.
- CEIP-Addictovigilance, CHU de Toulouse, Toulouse, France.
- Université Toulouse, CERPOP Inserm UMR1295, Toulouse, France.
- Population Health and Optimal Health Practices Research Axis, CHU de Québec Research Centre-University Laval Research Centre, Quebec City, Quebec, Canada.
- Faculty of Pharmacy, University Laval, Quebec City, Quebec, Canada.
- Centre D'excellence sur le Vieillissement de Québec, Centre Intégré Universitaire de Soins et Services Sociaux de la Capitale Nationale, Quebec City, Quebec, Canada.
ORCID-Profile: Marie-Laure Laroche, Emilie Jouanjus, Edeltraut Kröger, Arsène Zongo
Zitieren
APA
Laroche, M. L., Labetoulle, M., Jouanjus, E., Kröger, E., & Zongo, A. (2025). Cannabinoids and Adverse Convulsive Effects: A Pharmacovigilance and Addictovigilance Analysis of Cases Reported in France. Fundamental & Clinical Pharmacology. https://doi.org/10.1111/fcp.70028
Vancouver
Laroche ML, Labetoulle M, Jouanjus E, Kröger E, Zongo A. Cannabinoids and Adverse Convulsive Effects: A Pharmacovigilance and Addictovigilance Analysis of Cases Reported in France. Fundamental & Clinical Pharmacology. 2025. doi:10.1111/fcp.70028
BibTeX
@article{Laroche2025,
author = {Laroche, Marie-Laure and Labetoulle, Marion and Jouanjus, Emilie and Kröger, Edeltraut and Zongo, Arsène},
title = {Cannabinoids and Adverse Convulsive Effects: A Pharmacovigilance and Addictovigilance Analysis of Cases Reported in France},
journal = {Fundamental & Clinical Pharmacology},
year = {2025},
doi = {10.1111/fcp.70028}
}
EUVIMED